Sotagliflozin is an oral dual sodium-glucose co-transporter types 1 and 2 (SGLT1/SGLT2) inhibitor. The FDA panel voted against the approval of sotagliflozin for patients with type 1 diabetes and ...

FSH levels were independently associated with an increased risk for hip fracture among older men and women regardless of bone density.

Topline results were announced from a phase 3 clinical trial evaluating subcutaneous semaglutide in obesity and knee osteoarthritis.

Heterozygous familial hypercholesterolemia was associated with increased type 2 diabetes risk, especially among those with obesity and statin use.